Managing Liver Tumours through targeted IR treatments.

Liver tumours can be frightening to hear about, especially when the diagnosis is new and the words used in clinic sound highly technical. For many Singaporeans, the first concern is not only whether the tumour is cancerous, but also what treatment can control it while preserving enough healthy liver function to maintain daily life. This is where interventional radiology, often shortened to IR, plays an important role. Using image guidance from ultrasound, CT, or fluoroscopy, interventional radiologists can treat selected liver tumours through small access points, often without open surgery. For patients, that can mean shorter recovery time, less pain, and in some cases a treatment plan that can be repeated or combined with surgery, systemic therapy, or transplant assessment.

Liver tumours are not one single disease. They may be primary liver cancers such as hepatocellular carcinoma, which is the most common primary liver cancer, or secondary tumours, which means cancer that has spread to the liver from another organ such as the colon. Some liver tumours are benign, meaning non-cancerous, but they still sometimes need careful assessment. In Singapore, liver cancer remains a significant health concern because chronic hepatitis B, hepatitis C, fatty liver disease, and other liver conditions can increase risk over time. This makes early assessment and a personalised treatment plan especially important. Targeted IR treatments are now an established part of that plan for many patients, particularly when surgery is not suitable, when the tumour is in a difficult location, or when a local treatment is needed alongside other cancer therapies.

Understanding liver tumours and why local treatment matters

When doctors talk about treating liver tumours, they consider several factors at the same time, including tumour size, number of lesions, location in the liver, liver function, and whether the cancer has spread outside the liver. The liver is a highly vascular organ, meaning it has a rich blood supply. That fact is important because many IR treatments work by targeting the tumour’s blood supply, delivering heat or cold directly into the lesion, or injecting therapy into the artery that feeds it. These local treatments are designed to act where the tumour is, while limiting damage to surrounding healthy tissue.

For patients, local control can matter a great deal. In some cases, it may be used with curative intent, especially for very early stage disease or small tumours. In other situations, it may be used to slow growth, relieve symptoms, bridge a patient to surgery or liver transplant, or reduce tumour burden before additional treatment. The choice depends on multidisciplinary review, which usually involves hepatologists, medical oncologists, surgeons, radiologists, and interventional radiologists working together. This team-based approach is widely used in established cancer centres, including those in Singapore.

Primary and secondary liver tumours

Primary liver tumours begin in the liver itself. The most common type is hepatocellular carcinoma, often linked to chronic liver disease or cirrhosis. Another less common type is intrahepatic cholangiocarcinoma, which starts in the bile ducts within the liver. Secondary liver tumours are metastases, meaning cancer cells that have spread from elsewhere. The liver is a common site for metastasis because of its blood flow and filtering role. Treatment goals differ between these groups, so a biopsy or imaging-based diagnosis may be needed before deciding on the right IR procedure.

Why surgery is not always the first option

Surgery can be highly effective for selected patients, but not everyone is suitable. Some tumours are too close to major vessels or bile ducts, some patients have limited liver reserve because of cirrhosis, and some have medical conditions that increase operative risk. In those situations, targeted IR treatments may offer a practical, evidence-based alternative or complement. The goal is not to replace every other treatment, but to provide an option that is matched to the patient’s anatomy, cancer stage, and overall health.

Targeted IR treatments commonly used for liver tumours

Interventional radiology refers to minimally invasive procedures performed using real-time imaging guidance. For liver tumours, the most commonly used IR treatments include thermal ablation, transarterial therapies, and selected catheter-based approaches. Each method has different strengths, and the best choice depends on tumour features and the patient’s liver function.

Radiofrequency ablation and microwave ablation

Thermal ablation destroys tumour tissue using heat. Radiofrequency ablation, or RFA, uses alternating electrical current to generate heat, while microwave ablation, or MWA, uses electromagnetic energy to raise tissue temperature. Both are performed by placing one or more needles directly into the tumour under imaging guidance. The heat causes cell death within the targeted area. These methods are often used for smaller tumours, especially when surgery is not ideal. MWA can sometimes create a larger and more predictable ablation zone than RFA, which may be useful in certain tumour locations, but the selection of technique depends on the case.

Because the needle is inserted directly into the tumour, accurate imaging is essential. Ultrasound is often used, sometimes with CT guidance or fusion imaging. Patients may receive sedation or general anaesthesia depending on the procedure, tumour location, and hospital protocol. The main advantage is precision, with treatment focused on the lesion and limited trauma to the surrounding liver.

Transarterial chemoembolisation, also known as TACE

Transarterial chemoembolisation, or TACE, is a catheter-based treatment delivered through the blood vessels. A small catheter is introduced, usually via the groin or wrist artery, and guided into the hepatic artery branches that supply the tumour. Chemotherapy is then delivered directly into the tumour-feeding artery, followed by embolic material that reduces blood flow. This dual effect, local chemotherapy plus blockage of arterial supply, helps starve the tumour while concentrating treatment where it is needed.

TACE is commonly used in patients with unresectable hepatocellular carcinoma who still have preserved liver function and no major vascular invasion or widespread extrahepatic spread. It is not a one-size-fits-all treatment. The liver’s remaining function must be carefully assessed, because reducing arterial blood flow too much can harm healthy tissue, especially in people with underlying cirrhosis. For suitable patients, TACE can help control tumour growth and may be repeated in selected cases based on response and tolerance.

Radioembolisation and selective internal radiation therapy

Radioembolisation, also called selective internal radiation therapy or SIRT in some settings, uses tiny radioactive microspheres delivered through the hepatic artery to deposit radiation inside the tumour. This treatment is highly localised and depends on careful mapping before therapy to ensure the particles go to the intended areas and do not cause harmful flow to other organs. It is used in selected patients with primary or secondary liver tumours, depending on the tumour biology, vascular anatomy, and prior treatments.

Before radioembolisation, patients usually undergo angiographic mapping to study the blood vessels and to identify any branches that might need to be protected or embolised. This planning step is central to safety. The procedure requires close coordination between the interventional radiology team and oncology specialists. In selected patients, it may be considered when other local treatments are not appropriate, or when a more targeted radiation approach is preferable.

Other image-guided options

In some cases, IR teams may use cryoablation, which freezes tumour tissue, or percutaneous ethanol injection, which involves injecting alcohol into the lesion. These are used less commonly now and are highly case-dependent. Drainage procedures or biliary interventions may also be needed if tumours cause obstruction or complications. The broader field of IR also supports biopsy, vascular access, and complication management, making it an important part of liver cancer care beyond tumour destruction alone.

How doctors decide which IR treatment is appropriate

Choosing the right procedure is not simply about the tumour’s size. It is about the full clinical picture. A patient with a small hepatocellular carcinoma and good liver reserve may be suitable for ablation. Another patient with multiple tumours but preserved liver function may benefit more from TACE. A person with limited treatment options after prior therapies may be considered for radioembolisation. The decision is personal, technical, and multidisciplinary.

Key factors in treatment planning

  • Tumour size and number, because very small lesions may be ideal for ablation, while larger or multifocal disease may need arterial therapy.
  • Tumour location, especially proximity to major bile ducts, large vessels, or the diaphragm, because some positions carry different risks.
  • Liver function, including whether there is cirrhosis, jaundice, or reduced synthetic function.
  • Overall fitness, including heart, kidney, and lung health, as these affect procedural safety and recovery.
  • Previous treatment history, such as surgery, chemotherapy, liver transplant evaluation, or prior IR procedures.
  • Patient goals, whether the focus is cure, local control, symptom relief, or bridge therapy.

In Singapore, where care often involves tertiary hospitals with multiple specialists, this type of coordinated planning is standard practice. Patients may also be monitored with blood tests and contrast imaging at intervals after treatment to assess response. A good treatment plan takes into account not only the tumour, but also the patient’s daily life, work demands, family responsibilities, and ability to attend follow-up appointments.

What patients can expect before, during, and after treatment

Understanding the pathway can reduce anxiety. While each procedure is different, most begin with a consultation that reviews imaging scans, blood test results, medications, and any history of bleeding problems or liver disease. Some patients need additional scans or angiographic mapping before treatment. Blood-thinning medications may need to be adjusted, but this must always be done under medical supervision. The care team will also check kidney function, clotting profile, and liver enzymes.

The procedure day

On the day of treatment, patients are usually admitted for observation. Depending on the procedure, they may receive local anaesthesia with sedation or general anaesthesia. The procedure itself can take anywhere from under an hour to several hours, depending on complexity. After ablation, patients may feel discomfort, mild fever, or nausea for a short period. After TACE or radioembolisation, some may experience post-embolisation symptoms such as abdominal pain, tiredness, low-grade fever, or reduced appetite. These symptoms are commonly managed with supportive medications and monitoring.

Recovery and follow-up

Recovery time is often shorter than open surgery, but follow-up is essential. Imaging is usually performed after a period of healing to determine whether the tumour has been adequately treated. In some cases, more than one session is needed. The liver can often tolerate staged treatment better than a major operation, but that decision depends on liver reserve and tumour response. Patients are also watched for complications such as bile duct injury, liver failure, infection, bleeding, or abscess formation, although not every patient will experience these issues.

For Singapore patients balancing treatment with work and family life, the minimally invasive nature of IR can be meaningful. A person may return home sooner and resume routine activities earlier than after surgery, but they still need to plan for rest, transportation, and follow-up visits. Having a caregiver present after discharge can be helpful, especially on the first day after sedation or anaesthesia.

Living with liver tumours in Singapore, practical considerations and next steps

Singapore’s healthcare environment offers access to specialist liver care, imaging, and multidisciplinary cancer services. For patients and families, the most practical step is usually to seek timely assessment when a liver lesion is detected on ultrasound, CT, MRI, or blood testing. Not every lesion is cancer, but every suspicious lesion deserves proper workup. If a tumour is confirmed, ask how liver function, tumour size, and tumour location influence the recommended treatment. Ask whether the goal is cure, control, or preparation for another therapy. These questions help patients understand why a particular IR treatment is suggested.

It also helps to address underlying liver health. Viral hepatitis screening, alcohol moderation, weight management, diabetes control, and treatment of fatty liver disease may all be part of long-term care. If chronic hepatitis B or C is present, ongoing specialist follow-up is important because the underlying disease can influence both treatment choice and future risk. For some patients, managing the liver condition itself is just as important as treating the tumour.

Targeted IR treatments are not suitable for every liver tumour, but for the right patient, they can be a powerful part of care. They offer precision, preserve more normal tissue than many traditional approaches, and can often be integrated with surgery, systemic therapy, or surveillance. If you or a family member has been told there is a liver tumour, the most useful next step is to discuss a multidisciplinary plan with a specialist team. The right decision depends on the tumour type, the state of the liver, and the overall treatment goal. With a carefully chosen strategy, many patients can move forward with greater clarity and a treatment plan that is both medically sound and tailored to their situation.

Medical note: This article is for general information only and does not replace consultation with a qualified doctor. Treatment decisions for liver tumours should be made with a specialist who can interpret scans, blood tests, and the patient’s full medical history.